There are a few things that differentiate successful multinational companies from local, emerging companies. One of these things is the degree of control on the supply chain. Since its foundation in 1998, Seattle Genetics lacked the financial muscle to market its product internationally. As a result, the company cut a deal with Takeda Oncology. However, things are different today. The company has gained significant international expertise and has the capability to raise the required capital outlay. There is nothing now standing between Seattle Genetics and asserting its commitment to the global market. The man who will lead this global charge is company CEO and President Clay Siegall.
Seattle Genetics is an emerging biotechnology company that deals solely in oncological products. The company was founded in 1998 and is estimated to be worth close to $10 billion today. Where many have failed, the company has been able to thrive in the field of cancer research, particularly in regards to the development of antibody-drug conjugates (ADCs). These ADCs have the ability to kill cancer cells by delivering toxins inside them that eventually lead to their death. One of the ADCs Seattle Genetics already has in the market, Adcetris is already doing quite well in the market. The company’s value has, as a result, grown more than 50 years in the last year alone. Clay Siegall is quite confident that the range of drugs still being developed by the company are promising enough to justify the billions of dollars the company will spend to commercialize its products globally. Truth be told, however, it is the presence of Clay Siegall that justifies the huge outlay.
More on Clay Siegall
Clay Siegall is a B.S, Zoology graduate from the University of Maryland. He has also built on his undergraduate qualification with a Doctor of Philosophy (Ph.D.) in Genetics from the George Washington University. He has relied on his scientific background to build Seattle Genetics into the huge company it now. He has been able to do this by combining an innate passion for helping people with strong scientific innovation ideals. He has as a result been at the helm of Seattle Genetics since its formation in 1998.
Clay Siegall’s successes have not gone unnoticed, and he has on certain occasions been honored and awarded. In 2012 he was named the Entrepreneur of the Year by Pacific Northwest Ernst and Young. A year later, the University of Maryland honored him as the Alumnus of the Year for the fields of Computer, Math and Natural Sciences.